文献速递白血病造血干细胞移植与细胞治疗

靶向CD52的嵌合抗原受体修饰T细胞的制备及其抗白血病效应

[Preparation of CD52-targeted chimeric antigen receptor-modified T cells and their anti-leukemia effects].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

研究通过分子克隆构建含4-1BB共刺激域的二代CD52 CAR,经慢病毒转导T细胞制备CD52 CAR-T,并在体外验证其对CD52阳性白血病细胞系的特异性杀伤、脱颗粒与细胞因子释放效应。

要点

  • 成功构建pCDH-CD52 scFv-CD8α-4-1BB-CD3ζ-GFP载体并制备CD52 CAR-T细胞。
  • CD52 CAR-T可清除CD52阳性T细胞并保持体外长期扩增能力。
  • CD52 CAR-T特异性杀伤CD52阳性HuT78-19t细胞,对CD52阴性MOLT4-19t无明显杀伤。

核心结论

  • 成功制备了具有抗白血病作用的CD52 CAR-T细胞,可能为进一步的靶向CD52免疫治疗奠定基础。

研究设计与样本

  • 应用分子克隆技术构建以CD52为抗原结合区、4-1BB为共刺激分子的二代CAR,经慢病毒载体包装后感染T细胞制备CD52 CAR-T细胞。
  • 通过流式细胞术检测CD52 CAR-T细胞CD4、CD8亚群及分化状态。
  • 通过体外杀伤实验、脱颗粒实验及细胞因子释放等功能实验观察CD52 CAR-T对CD52阳性白血病细胞的特异性细胞毒作用。

主要发现

  • 感染CD52 CAR表达载体第6天,CD52 CAR-T组CD52阳性T细胞为(4.48±4.99)%,Vector-T组为(56.58±19.8)%,P=0.011。
  • CD52 CAR-T组培养后期增殖速度高于Vector-T组,且CD52 CAR可促进向中心记忆及效应记忆T细胞分化、减少向终末效应细胞分化。
  • 效靶比1∶1共培养24 h,CD52 CAR-T组HuT78-19t细胞残留(2.66±1.60)%,MOLT4-19t细胞存活(56.66±5.74)%,P<0.001。
  • 脱颗粒实验显示HuT78-19t对CD52 CAR-T的激活为(57.34±11.25)%,MOLT4-19t为(13.06±4.23)%,P<0.001。
  • 共培养48 h上清中CD52 CAR-T组IFN-γ(3706±226)pg/ml、TNF-α(1732±560)pg/ml,高于MOLT4-19t细胞组IFN-γ(1577±846)pg/ml、TNF-α(74±12)pg/ml,P值均<0.01。

临床怎么用

  • 原文结论仅指出成功制备具有抗白血病作用的CD52 CAR-T细胞,可能为进一步的靶向CD52免疫治疗奠定基础,未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To construct chimeric antigen receptor (CAR) T cells targeting CD52 (CD52 CAR-T) and validate the effect of CD52 CAR-T cells on CD52-positive leukemia. Methods: A second-generation CD52-targeting CAR bearing 4-1BB costimulatory domain was ligated into a lentiviral vector through molecular cloning. Lentivirus was prepared and packaged by 293 T cells with a four-plasmid system. Fluorescein was used to label cell surface antigens to evaluate the phenotype of CD52 CAR-T cells after infection. Flow cytometry and ELISA were used to evaluate the specific cytotoxicity of CD52 CAR-T cells to CD52-positive cell lines in vitro. Results: ①A pCDH-CD52scFv-CD8α-4-1BB-CD3ζ-GFP expressing plasmid was successfully constructed and used to transduce T cells expressing a novel CD52-targeting CAR. ②On day 6, CD52-positive T cells were almost killed by CD52-targeted CAR-T post lentivirus transduction [CD52 CAR-T (4.48 ± 4.99) %, vs Vector-T (56.58±19.8) %, P=0.011]. ③T cells transduced with the CAR targeting CD52 showed low levels of apoptosis and could be expanded long-term ex vivo. ④The CD52 CAR could promote T cell differentiation into central and effector memory T cells, whereas the proportion of T cells with a CD45RA(+) effector memory phenotype were reduced. ⑤CD52 CAR-T cells could specifically kill CD52-positive HuT78-19t cells but had no killing effect on CD52-negative MOLT4-19t cells. For CD52 CAR-T cells, the percentage of residual of HuT78-19t cells was (2.66±1.60) % at an the E:T ratio of 1∶1 for 24 h, while (56.66±5.74) % of MOLT4-19t cells survived (P<0.001) . ⑥The results of a degranulation experiment confirmed that HuT78-19t cells significantly activated CD52 CAR-T cells but not MOLT4-19t cells[ (57.34±11.25) % vs (13.06± 4.23) %, P<0.001]. ⑦CD52 CAR-T cells released more cytokines when co-cultured with HuT78-19t cells than that of vector-T cells [IFN-γ: (3706±226) pg/ml, P<0.001; TNF-α: (1732±560) pg/ml, P<0.01]. Conclusions: We successfully prepared CD52 CAR-T cells with anti-leukemia effects, which might provide the foundation for further immunotherapy. 目的: 构建一种靶向CD52的嵌合抗原受体T细胞(CD52 CAR-T),探索其对CD52(+)白血病的治疗效果。 方法: 应用分子克隆技术构建以CD52为抗原结合区的CD52 scFv、4-1BB为共刺激分子的二代CAR-T细胞。慢病毒载体包装后感染T细胞,制备CD52 CAR-T细胞,通过流式细胞术检测CD52 CAR-T细胞CD4、CD8细胞亚群及其分化状态。通过体外杀伤实验、脱颗粒实验及细胞因子的释放等功能实验,观察CD52 CAR-T细胞对CD52(+)白血病细胞的特异性细胞毒作用。 结果: ①成功构建了pCDH-CD52 scFv-CD8α-4-1BB-CD3ζ-GFP表达载体,感染人T细胞,获得靶向CD52的CAR-T细胞。②感染CD52 CAR表达载体的第6天,T细胞中表达CD52的细胞可被清除[CD52 CAR-T组CD52(+) T细胞为(4.48±4.99)%,Vector-T组为(56.58±19.8)%,P=0.011]。③CD52 CAR-T的自我杀伤不会影响T细胞的增殖,培养后期CD52 CAR-T组的增殖速度高于Vector-T组。④T细胞表型检测发现CD52 CAR可以促进CAR-T细胞向中心记忆T细胞及效应记忆T细胞分化,减少CAR-T细胞向终末效应细胞分化。⑤CD52 CAR-T细胞与HuT78-19t及MOLT4-19t靶细胞以效靶比1∶1共培养24 h,HuT78-19t细胞可被清除,而对MOLT4-19t细胞无明显杀伤作用[(2.66±1.60)%对(56.66%±5.74)%,P<0.001]。⑥脱颗粒实验显示,HuT78-19t细胞对CD52 CAR-T细胞的激活作用显著高于MOLT4-19t细胞[(57.34±11.25)%对(13.06±4.23)%,P<0.001]。⑦CD52 CAR-T与HuT78-19t细胞共培养48 h上清中细胞因子分泌水平[IFN-γ(3706±226)pg/ml、TNF-α(1732±560)pg/ml]远高于MOLT4-19t细胞组[IFN-γ(1577±846)pg/ml、TNF-α(74±12)pg/ml](P值均<0.01)。 结论: 该研究成功制备了具有抗白血病作用的CD52 CAR-T细胞,为进一步的靶向CD52的免疫治疗奠定了基础。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu Y, Liu Y, Tang KJ, et al. [Preparation of CD52-targeted chimeric antigen receptor-modified T cells and their anti-leukemia effects]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35680625. doi:10.3760/cma.j.issn.0253-2727.2022.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。